Everyone wants to talk about cannabis rescheduling 2026 like the finish line already got crossed. It did not. In April, the Justice Department moved state-legal medical cannabis and FDA-approved cannabis drug products to Schedule III — a real, historic change. But the adult-use side of the market, the part most operators actually live in, is still Schedule I and still working its way through a federal hearing.
That gap between what happened and what people think happened is where deals go to die. If you price a cannabis company in 2026 as though full federal rescheduling and blanket tax relief already landed, you are buying a fantasy at a premium. Here is how to price the reality instead.
What You’ll Learn
Where Cannabis Rescheduling 2026 Actually Stands
Let’s be precise, because precision is the whole game here. On April 23, 2026, the Department of Justice issued a final order reclassifying state-legal medical cannabis and cannabis in FDA-approved drug products from Schedule I to Schedule III, effective on publication in the Federal Register on April 28, 2026.
Everything else stayed put. Per the Federal Register notice, marijuana that is neither in an FDA-approved product nor tied to a qualifying state medical license remains a Schedule I controlled substance. Then the DEA set an expedited hearing on broader rescheduling that began June 29, 2026 and is set to conclude no later than July 15, 2026.
So as of this summer, cannabis rescheduling 2026 is a split screen: medical and FDA-approved products on Schedule III, adult-use still on Schedule I, and a hearing record that is not even closed yet. For the deeper backstory, see our explainer on medical marijuana rescheduling and the earlier rescheduling executive order.
The Fantasy Inflating Valuations
Here is the story sellers are telling: “Rescheduling is basically done, 280E is going away, multiples are going up — pay me now before the re-rate.” It is a great pitch. It is also selling a result that has not been decided.
The fantasy has three moving parts, and every one of them is a place a buyer overpays. First, that the June hearing automatically ends in full rescheduling. Second, that a favorable outcome applies to adult-use operators the day the gavel drops. Third, that tax relief flows to everyone at once. None of those are guaranteed, and pricing them as certainties is how a 2026 cannabis deal quietly becomes a 2028 write-down.
Notice what the fantasy quietly skips: the difference between a headline and a rule. A DOJ press release, a hearing date, even a recommended decision are not the same as a final rule with an effective date. Markets price emotion; disciplined buyers price documents. When a seller hands you optimism, ask to see the Federal Register citation — and price the gap between the two.
What Schedule III Does and Doesn’t Do to 280E
Section 280E of the tax code blocks cannabis businesses from deducting ordinary expenses because they “traffic” a Schedule I or II substance. Move off Schedule I or II, and 280E stops applying. That is the whole reason rescheduling is worth real money.
But read the fine print. The April order lifted Schedule I status only for the medical and FDA-approved slice. An adult-use dispensary that is not operating under a qualifying state medical license is still a Schedule I business — which means it is still living under 280E until broader rescheduling is finalized. Buyers who assume the tax math already flipped for a recreational operator are mispricing the single biggest line item in the model. If tax posture is central to your deal, so is how the holding company is structured.
There is also a retrospective angle worth diligencing: businesses that now qualify for Schedule III treatment may look hard at amended returns and refund claims for tax paid under 280E. That is a potential asset — but it is contingent, contested, and absolutely not something to fund at full value in a purchase price today.
Five Ways to Price Rescheduling Into a Deal
You do not have to bet the deal on a hearing outcome. You structure around it. Five tools do most of the work:
- Contingent earnouts tied to the Federal Register: Peg a chunk of the price to the actual publication of a final adult-use rescheduling rule — not to headlines, not to a press release.
- Scheduling reps and warranties: Make the seller represent the company’s current control-substance status and tax posture, with indemnity if it is not what they claimed.
- A 280E true-up: Escrow an amount sized to the tax exposure that survives if rescheduling slips, and release it only when relief is real.
- Two-track valuation: Price the business on today’s Schedule I economics, with a defined step-up if and when the status changes.
- Walk and reprice rights: Give yourself a defined exit or price adjustment if the hearing outcome or effective date lands outside your assumptions.
This is the same discipline that protects any regulated-asset purchase, from a federal DEA license question to an import-export permit: price what is decided, escrow what is pending.
Two Term Sheets, One Company
Picture two buyers looking at the same adult-use operator doing $10 million in revenue. Buyer A prices it as a “post-rescheduling” business: full deductions, clean tax posture, and a fat multiple built on relief that has not actually reached recreational cannabis. Buyer B prices it as what it is today — a Schedule I business still carrying 280E — and layers on an earnout that pays the seller more if and when adult-use rescheduling is finalized.
Buyer A wins the auction and inherits the risk. If the effective date slips or the outcome narrows, Buyer A overpaid for a tax benefit the company never had. Buyer B either wins at a rational price or walks away from a deal that was overpriced anyway. In a market defined by cannabis rescheduling 2026 uncertainty, being Buyer B is not timid — it is how you avoid financing someone else’s optimism.
None of these tools require you to predict the hearing outcome. They require you to admit that you cannot — and to let the contract, not your optimism, carry the risk.
The Timeline Risk Nobody Prices
The hearing wrapping up by July 15, 2026 is not the same as a final rule. After a hearing closes, there is a recommended decision, a final agency action, a comment and review cycle, and the ever-present possibility of litigation. Any of those can move the effective date by quarters.
That timeline risk is real money when your model assumes 280E relief starting on a specific date. A deal priced on “rescheduling by year-end” and a deal priced on “rescheduling, effective date unknown” are two different deals. Smart operators — the ones who structure for reality instead of hoping for headlines — price the second one. For the operational and valuation side of that analysis, cannabis consulting and valuation support pairs well with deal counsel, and complex transactions belong with experienced cannabis deal attorneys.
Frequently Asked Questions
Is cannabis fully rescheduled in 2026?
No. As of mid-2026, only state-legal medical cannabis and FDA-approved cannabis products moved to Schedule III, effective April 28, 2026. Adult-use cannabis remains Schedule I while a broader rescheduling hearing runs its course. Verify the current status before relying on it.
Does Schedule III end 280E for every cannabis business?
Not yet. 280E stops applying once a business is off Schedule I or II. The 2026 order only moved the medical and FDA-approved slice, so adult-use operators still on Schedule I remain subject to 280E until broader rescheduling is finalized.
How should cannabis rescheduling 2026 affect a purchase price?
Price the business on the economics that exist today and use earnouts, escrows, and a tax true-up to capture the upside if and when rescheduling reaches adult-use. Paying a full “Schedule III multiple” now for a Schedule I business is where buyers overpay.
When will adult-use cannabis be rescheduled?
There is no fixed date. The DEA hearing on broader rescheduling was set to conclude by July 15, 2026, but a hearing is not a final rule. A recommended decision, final agency action, and possible litigation can each move the effective date, so treat any specific date as an assumption to verify.
Next Steps
Cannabis rescheduling 2026 is real, partial, and still in motion — which is exactly why the deals getting done well are the ones priced on facts, not on the fantasy. Structure for what is decided, escrow for what is pending, and let the upside come to you.
Pressure-test your deal. Schedule a consultation before you sign a term sheet built on assumptions about rescheduling.
This article is general information, not legal advice. No attorney-client relationship is created by reading it. It describes federal cannabis rescheduling developments as of July 2026, which are changing quickly; confirm the current status before acting. Attorney Advertising.
